This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin Therapeutics To Hold Conference Call To Provide Update Following Company's Annual Meeting Of Shareholders -- New Phone Number For Audio Portion Of Presentation

ATLANTA , May 23, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders.  Due to technological difficulties, a different phone number than previously circulated will be used for accessing the call.  The audio portion of the call can now be accessed by dialing (888) 582-3528 (toll-free within the United States) or (847) 944-7361 (toll, from outside the United States). The passcode for participants is still 7827311#.

The conference call and presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at www.galectintherapeutics.com.

Please log in approximately 10 minutes before the event to ensure a timely connection.

The webcast will also be archived on the Company's website.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at http://www.galectintherapeutics.com.

SOURCE Galectin Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,093.89 +55.92 0.31%
S&P 500 2,114.46 +5.54 0.26%
NASDAQ 5,055.2170 -5.0290 -0.10%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs